The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

Drug Target Review

SEPTEMBER 4, 2023

10 Reported cAMP as the second messenger signalling molecule conserved from bacteria to humans and modulates several biological processes, including protein expression, gene transcription, and cell development and differentiation. link] Ojewale Kayode (2018). Doi.org/10.1038/s41592-019-0614-5 Ishita, G., Suruchi, A., Nilmar, S.

Drugs 111

Drugs RNA DNA Disease 111

The Pharma Data

JANUARY 13, 2021

Structure 3:1031-1039 (1995) 3 Waters J, Biocentury ; October 26, (2018) 4 NCT02273960; ClinicalTrials.gov ; “Study to Evaluate Safety and Efficacy in Adult Subjects With ITP (ITP)”; results posted April 1, 2019, updated July 29, 2019 and accessed Jan 11, 2021 5 Ferrant JL et al., 1 Lederman, S. International Immunol. (11):1583

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

Drug Discovery World

SEPTEMBER 5, 2022

Modulations in protein expression levels or the presence of dysfunctional proteins observed in individuals with specific mutations act as biomarkers in selecting patients for targeted therapies. . When selecting patients for therapy, we currently look at variants that directly affect protein expression or function.

Drug Development 130

Drug Development Drugs Protein Expression Therapies 130

Drug Discovery World

APRIL 30, 2024

For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 mRNA-based approaches can produce proteins / peptides by using protein synthesis which is processed in a transfected cell 1.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

The Pharma Data

APRIL 8, 2021

EVRYSDI was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. Applications are under review with numerous regulators. At this time, EVRYSDI has been approved in 38 countries and submitted in a further 33 countries. Europe and Japan.

Clinical Trials 52

Clinical Trials Trials Disease Nurses 52

The Pharma Data

SEPTEMBER 2, 2020

Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, suggesting that important functions of the immune system may be preserved. Applications are under review with numerous regulators, including in the EU and China.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52